RxDoctor Payments DataLook up a doctor →

Charles Bodine, MD

Hematology & Oncology · Athens, GANPI 1740669928

Payments from drug & device makers

$350,432in general payments, 2019–2025

Across 495 payments — averaging $707.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$213K
  • Bristol Myers Squibb$92K
  • E.r. Squibb & Sons, L.L.C.$35K
  • Novartis$3K
  • Johnson & Johnson$808
  • Merck$552
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$9,25876%
  • Education$5014%
  • Other$2,49820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$350,432 in reported general payments places this provider in the 80th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$3,384,612
Medicare patients
631
Services billed
113,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide13$217,047
KisqaliRibociclib Succinate13$181,936
Neulasta OnproPegfilgrastim14$99,743
Abiraterone Acetate24$37,492
ProcritEpoetin Alfa32$22,244
EliquisApixaban34$20,333
XareltoRivaroxaban25$18,610
Fulvestrant20$12,651
Tamoxifen Citrate42$929
Anastrozole65$829
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$763
Ondansetron Hcl25$577
Oxycodone Hcl40$577
Hydroxyurea14$498
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$91,841$217,04713 claims
NovartisKisqali$3,349$181,93613 claims
Johnson & JohnsonProcrit, Xarelto$808$40,85457 claims
PfizerEliquis$364$20,33334 claims
Lilly USA, LLCOlanzapine$147$24819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →